Anuoluwapo Eniola Sopeyin

Anuoluwapo Sopeyin practices at Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland.

Anuoluwapo Sopeyin's NPI, 1568090827, was assigned on March 31, 2020. Anuoluwapo Sopeyin graduated from Yale University School of Medicine in 2020. Anuoluwapo Sopeyin holds Maryland license D0100964.

Anuoluwapo Sopeyin's primary practice is Johns Hopkins Hospital Nelson/Harvey Building, at 600 N Wolfe St, Baltimore, MD 21287 in Baltimore City. The practice phone is (855) 662-3017.

Anuoluwapo Sopeyin's primary practice is Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland. Anuoluwapo Sopeyin is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Anuoluwapo Sopeyin to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Anuoluwapo Sopeyin practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Anuoluwapo Sopeyin's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Anuoluwapo Sopeyin is licensed in Maryland.

CMS data shows 205 Medicare services from Anuoluwapo Sopeyin across 8 procedure codes in 2024, for 158 Medicare patients. Medicare paid $28,394 for them.

CMS counts 158 Medicare patients who saw Anuoluwapo Sopeyin in 2024. The largest group is 65 to 74, with 74 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 17% are also on Medicaid. Their average risk score is 1.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Anuoluwapo Sopeyin's median patient age at 63, with 47% women.

In 2024, Anuoluwapo Sopeyin wrote 502 Medicare Part D claims for 162 patients. 68% of them were for generic drugs. CMS names the drug for 462 of them, across 8 drugs with 11 or more claims each, at $8,963 in total drug cost. In 2023, CMS named 465 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Anuoluwapo Sopeyin for performance year 2024, reported as part of a group.

Dmand AI links 12 papers to Anuoluwapo Sopeyin, published from 2018 to 2024. 2018 was the busiest year, with 2. The most frequent topics are Amblyopia, Cell-Free Nucleic Acids and Cholesterol. Anuoluwapo Sopeyin's most frequent co-authors are Elijah Essandoh Paintsil, MD, Kemal Marc Akat, MD, MS, PhD and Thomas Diacovo.

CMS Open Payments shows 3 general payments to Anuoluwapo Sopeyin from 1 drug or device company in 2024. Travel and lodging make up the largest share, 83% of the total. Glaukos Corporation paid the most, $1,704.

Anuoluwapo Sopeyin graduated from Yale University School of Medicine in 2020.